Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements
Ernexa Therapeutics (Nasdaq: ERNA), a biotechnology company focused on cell therapies for cancer and autoimmune diseases, has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). The company received formal notice from Nasdaq on July 1, 2025, confirming its continued listing status.
CEO Sanjeev Luther reaffirmed the company's commitment to advancing their pipeline, with plans to initiate their first clinical trial in early 2026. The company's focus remains on developing engineered cell therapies for ovarian cancer and autoimmune disease patients.
Ernexa Therapeutics (Nasdaq: ERNA), una società biotecnologica specializzata in terapie cellulari per il cancro e le malattie autoimmuni, ha nuovamente soddisfatto il requisito minimo del prezzo di offerta stabilito da Nasdaq secondo la Regola di Quotazione 5550(a)(2). La società ha ricevuto una comunicazione ufficiale da Nasdaq il 1° luglio 2025, che conferma il mantenimento della sua quotazione.
Il CEO Sanjeev Luther ha ribadito l’impegno dell’azienda nel portare avanti il proprio portafoglio di progetti, con l’intenzione di avviare il primo trial clinico all’inizio del 2026. L’attenzione dell’azienda resta focalizzata sullo sviluppo di terapie cellulari ingegnerizzate per pazienti affetti da cancro ovarico e malattie autoimmuni.
Ernexa Therapeutics (Nasdaq: ERNA), una empresa biotecnológica centrada en terapias celulares para el cáncer y enfermedades autoinmunes, ha recuperado el cumplimiento del requisito mínimo de precio de oferta según la Regla de Cotización 5550(a)(2) de Nasdaq. La compañía recibió una notificación formal de Nasdaq el 1 de julio de 2025, confirmando la continuidad de su cotización.
El CEO Sanjeev Luther reafirmó el compromiso de la empresa para avanzar en su cartera de proyectos, con planes de iniciar su primer ensayo clínico a principios de 2026. El enfoque de la compañía sigue siendo el desarrollo de terapias celulares diseñadas para pacientes con cáncer de ovario y enfermedades autoinmunes.
Ernexa Therapeutics (나스닥: ERNA)는 암 및 자가면역 질환을 위한 세포 치료제에 주력하는 생명공학 회사로, 나스닥 상장 규칙 5550(a)(2)에 따른 최소 입찰 가격 요건을 다시 충족하였습니다. 회사는 2025년 7월 1일 나스닥으로부터 공식 통지를 받아 상장 지속 상태를 확인받았습니다.
CEO 산지브 루터는 회사의 파이프라인 진전을 위한 의지를 재확인하며, 2026년 초 첫 임상 시험을 시작할 계획임을 밝혔습니다. 회사는 난소암 및 자가면역 질환 환자를 위한 맞춤형 세포 치료제 개발에 계속 집중하고 있습니다.
Ernexa Therapeutics (Nasdaq : ERNA), une entreprise biotechnologique spécialisée dans les thérapies cellulaires pour le cancer et les maladies auto-immunes, a retrouvé la conformité avec l’exigence de prix minimum selon la règle de cotation Nasdaq 5550(a)(2). La société a reçu une notification officielle de Nasdaq le 1er juillet 2025, confirmant le maintien de sa cotation.
Le PDG Sanjeev Luther a réaffirmé l’engagement de l’entreprise à faire progresser son portefeuille, avec des plans pour lancer leur premier essai clinique début 2026. L’entreprise reste concentrée sur le développement de thérapies cellulaires conçues pour les patientes atteintes de cancer de l’ovaire et de maladies auto-immunes.
Ernexa Therapeutics (Nasdaq: ERNA), ein Biotechnologieunternehmen, das sich auf Zelltherapien für Krebs und Autoimmunerkrankungen spezialisiert hat, hat die Einhaltung der Mindestgebotspreisanforderung gemäß der Nasdaq-Listenregel 5550(a)(2) wiederhergestellt. Das Unternehmen erhielt am 1. Juli 2025 eine formelle Mitteilung von Nasdaq, die den fortbestehenden Börsenstatus bestätigt.
CEO Sanjeev Luther bekräftigte das Engagement des Unternehmens, die Pipeline voranzutreiben, mit Plänen, Anfang 2026 die erste klinische Studie zu starten. Der Fokus des Unternehmens liegt weiterhin auf der Entwicklung von gentechnisch hergestellten Zelltherapien für Patientinnen mit Eierstockkrebs und Autoimmunerkrankungen.
- Regained Nasdaq listing compliance, ensuring continued market access and visibility
- On track to initiate first clinical trial in early 2026
- Development pipeline includes both cancer and autoimmune disease treatments
- Previous non-compliance with Nasdaq listing requirements indicates recent stock price weakness
- No clinical trials currently active
- Revenue-generating products still years away from potential commercialization
CAMBRIDGE, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it has regained compliance with Nasdaq for continued listing and that its stock will continue to trade on The Nasdaq Stock Market.
On July 1, 2025, the company received formal notice from Nasdaq stating that Ernexa has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2) for continued listing.
“We remain laser-focused on advancing our programs toward the clinic, and we are on track to initiate our first clinical trial in early 2026,” said Sanjeev Luther, President and CEO of Ernexa Therapeutics. “Our team continues to execute with discipline and urgency – for the sake of the many patients living with ovarian cancer and autoimmune disease and their loved ones. We believe that our novel approach to engineered cell therapies holds significant promise for patients with serious and underserved conditions.”
About Ernexa Therapeutics
Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative stem cell therapies for the treatment of advanced cancer and autoimmune disease. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment, without needing patient-specific cell harvesting.
ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-102 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.
For more information, visit www.ernexatx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "objective," or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: progress and possible outcomes of the Company’s lead research project, ERNA-101, and future research projects. Forward-looking statements are based upon Ernexa's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa's risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law.
Media & Investor Relations Contact
FAQ
Why did Ernexa Therapeutics (ERNA) regain Nasdaq compliance?
When will Ernexa Therapeutics (ERNA) start its first clinical trial?
What therapeutic areas is Ernexa Therapeutics (ERNA) focusing on?
Who is the CEO of Ernexa Therapeutics (ERNA)?
What is the significance of Nasdaq compliance for Ernexa (ERNA) stock?
